$CELC
Celcuity Inc Stock $celc

$celc Overview Financials Valuation SEC Filings Company Website

2018 Q1 Form 10-K Financial Statement

#000114420418014940 Filed on March 15, 2018

Income Statement

Concept	2018 Q1	2016 Q4	2016
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$530.0K	$70.00K	$260.0K
YoY Change	488.89%		4.0%
% of Gross Profit
Research & Development	$1.546M	$840.0K	$3.065M
YoY Change	70.08%		52.48%
% of Gross Profit
Depreciation & Amortization	$39.74K	$20.00K	$73.06K
YoY Change	101.45%		21.77%
% of Gross Profit
Operating Expenses	$2.076M	$910.0K	$3.328M
YoY Change	108.9%		47.28%
Operating Profit	-$2.076M		-$3.328M
YoY Change	108.9%
Interest Expense	$0.00	$0.00	$0.00
YoY Change	-100.0%
% of Operating Profit
Other Income/Expense, Net	$108.4K		$18.02K
YoY Change
Pretax Income	-$1.968M	-$900.0K	-$3.310M
YoY Change	99.32%		46.48%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$1.968M	-$900.0K	-$3.310M
YoY Change	99.32%		46.48%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share	-$195.0K	-$96.05K	-$353.3K
COMMON SHARES
Basic Shares Outstanding	10.11M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2018 Q1	2016 Q4	2016
SHORT-TERM ASSETS
Cash & Short-Term Investments	$23.00M		$5.860M
YoY Change	369.39%		15.58%
Cash & Equivalents	$2.573M	$5.856M	$5.860M
Short-Term Investments	$20.43M
Other Short-Term Assets	$330.0K		$60.00K
YoY Change	450.0%		0.0%
Inventory
Prepaid Expenses	$246.7K	$0.00
Receivables
Other Receivables
Total Short-Term Assets	$23.33M	$5.912M	$5.910M
YoY Change	371.29%		15.43%
LONG-TERM ASSETS
Property, Plant & Equipment	$443.6K	$144.9K	$140.0K
YoY Change	216.84%		-22.22%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$6.950M
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$7.398M	$144.9K	$150.0K
YoY Change	5184.36%		-16.67%
TOTAL ASSETS
Total Short-Term Assets	$23.33M	$5.912M	$5.910M
Total Long-Term Assets	$7.398M	$144.9K	$150.0K
Total Assets	$30.73M	$6.057M	$6.060M
YoY Change	503.67%		14.34%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$130.0K	$331.5K	$330.0K
YoY Change	-43.46%		26.92%
Accrued Expenses	$653.0K	$113.8K	$110.0K
YoY Change	366.42%		450.0%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00		$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$783.0K	$445.4K	$450.0K
YoY Change	111.63%		60.71%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00		$0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$0.00		$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$783.0K	$445.4K	$450.0K
Total Long-Term Liabilities	$0.00		$0.00
Total Liabilities	$783.0K	$445.4K	$450.0K
YoY Change	111.63%		60.71%
SHAREHOLDERS EQUITY
Retained Earnings	-$3.975M	-$8.331M
YoY Change
Common Stock	$10.11K	$0.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$29.94M	$5.612M	$5.610M
YoY Change
Total Liabilities & Shareholders Equity	$30.73M	$6.057M	$6.060M
YoY Change	503.67%		14.34%

Cashflow Statement

Concept	2018 Q1	2016 Q4	2016
OPERATING ACTIVITIES
Net Income	-$1.968M	-$900.0K	-$3.310M
YoY Change	99.32%		46.48%
Depreciation, Depletion And Amortization	$39.74K	$20.00K	$73.06K
YoY Change	101.45%		21.77%
Cash From Operating Activities	-$1.448M	-$710.0K	-$2.888M
YoY Change	52.84%		45.87%
INVESTING ACTIVITIES
Capital Expenditures	$204.3K	-$10.00K	$40.90K
YoY Change	1868.2%		-151.13%
Acquisitions
YoY Change
Other Investing Activities	$1.400M
YoY Change
Cash From Investing Activities	$1.197M	-$10.00K	-$40.90K
YoY Change	-11631.51%		-48.87%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	183.8K	0.000	$3.718M
YoY Change			-22.54%
NET CHANGE
Cash From Operating Activities	-1.448M	-710.0K	-$2.888M
Cash From Investing Activities	1.197M	-10.00K	-$40.90K
Cash From Financing Activities	183.8K	0.000	$3.718M
Net Change In Cash	-67.13K	-720.0K	$789.1K
YoY Change	-92.99%		-71.2%
FREE CASH FLOW
Cash From Operating Activities	-$1.448M	-$710.0K	-$2.888M
Capital Expenditures	$204.3K	-$10.00K	$40.90K
Free Cash Flow	-$1.652M	-$700.0K	-$2.929M
YoY Change	72.52%		54.17%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2017	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2017	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2017	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2017	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
CY2017Q3	dei	Entity Public Float EntityPublicFloat	54831578	USD
CY2017	dei	Trading Symbol TradingSymbol	CELC
CY2018Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	10106464	shares
CY2017Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2639789	USD
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5856348	USD
CY2017Q4	us-gaap	Short Term Investments ShortTermInvestments	21556857	USD
CY2016Q4	us-gaap	Short Term Investments ShortTermInvestments	0	USD
CY2017Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	50000	USD
CY2016Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	50000	USD
CY2017Q4	us-gaap	Deposits Assets Current DepositsAssetsCurrent	27726	USD
CY2016Q4	us-gaap	Deposits Assets Current DepositsAssetsCurrent	5717	USD
CY2017Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	209708	USD
CY2016Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	0	USD
CY2017Q4	us-gaap	Assets Current AssetsCurrent	24484080	USD
CY2016Q4	us-gaap	Assets Current AssetsCurrent	5912065	USD
CY2017Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	280056	USD
CY2016Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	144912	USD
CY2017Q4	us-gaap	Assets Assets	31969510	USD
CY2016Q4	us-gaap	Assets Assets	6056977	USD
CY2017Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	71913	USD
CY2016Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	331534	USD
CY2017Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	506140	USD
CY2016Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	113825	USD
CY2017Q4	us-gaap	Liabilities Current LiabilitiesCurrent	578053	USD
CY2016Q4	us-gaap	Liabilities Current LiabilitiesCurrent	445359	USD
CY2017Q4	us-gaap	Liabilities Liabilities	578053	USD
CY2016Q4	us-gaap	Liabilities Liabilities	445359	USD
CY2016Q4	us-gaap	Members Capital MembersCapital	13349654	USD
CY2017Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2017Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	33388597	USD
CY2016Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2017Q4	us-gaap	Common Stock Value CommonStockValue	10087	USD
CY2016Q4	us-gaap	Common Stock Value CommonStockValue	0	USD
CY2016Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	593365	USD
CY2017Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-2007227	USD
CY2016Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-8331401	USD
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	31391457	USD
CY2016Q4	us-gaap	Stockholders Equity StockholdersEquity	5611618	USD
CY2017Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	31969510	USD
CY2016Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	6056977	USD
CY2017Q4	us-gaap	Members Capital MembersCapital	0	USD
CY2017	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4980427	USD
CY2016	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3064762	USD
CY2017	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	972518	USD
CY2016	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	263664	USD
CY2017	us-gaap	Operating Expenses OperatingExpenses	5952945	USD
CY2016	us-gaap	Operating Expenses OperatingExpenses	3328426	USD
CY2017	us-gaap	Operating Income Loss OperatingIncomeLoss	-5952945	USD
CY2016	us-gaap	Operating Income Loss OperatingIncomeLoss	-3328426	USD
CY2017	us-gaap	Interest Expense InterestExpense	451664	USD
CY2016	us-gaap	Interest Expense InterestExpense	0	USD
CY2017	us-gaap	Investment Income Interest InvestmentIncomeInterest	152879	USD
CY2016	us-gaap	Investment Income Interest InvestmentIncomeInterest	18018	USD
CY2017	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-298785	USD
CY2016	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	18018	USD
CY2017	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	7460640	shares
CY2016	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	6313089	shares
CY2017	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.84
CY2016	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.52
CY2017	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-6251730	USD
CY2016	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-3310408	USD
CY2017	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2016	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2017	us-gaap	Net Income Loss NetIncomeLoss	-6251730	USD
CY2016	us-gaap	Net Income Loss NetIncomeLoss	-3310408	USD
CY2016	celc	Members Units Issued During Period Value New Issue MembersUnitsIssuedDuringPeriodValueNewIssue	3718299	USD
CY2016	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition	141408	USD
CY2017	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition	677371	USD
CY2016	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Other Longterm Incentive Plans Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationOtherLongtermIncentivePlansRequisiteServicePeriodRecognition	45898	USD
CY2017	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Other Longterm Incentive Plans Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationOtherLongtermIncentivePlansRequisiteServicePeriodRecognition	197015	USD
CY2017	celc	Adjustments To Additional Paid In Capital Warrant Issued To Unsecured Convertible Promissory Note Holders AdjustmentsToAdditionalPaidInCapitalWarrantIssuedToUnsecuredConvertiblePromissoryNoteHolders	776717	USD
CY2017	celc	Adjustments To Additional Paid In Capital Warrant Issued To Placement Agent AdjustmentsToAdditionalPaidInCapitalWarrantIssuedToPlacementAgent	286999	USD
CY2017	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	0	USD
CY2017	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	22466986	USD
CY2017	celc	Adjustments To Additional Paid In Capital Warrant Issued To Underwriter AdjustmentsToAdditionalPaidInCapitalWarrantIssuedToUnderwriter	784111	USD
CY2017	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	6840318	USD
CY2017	celc	Stock Issued Convertible Conversion Of Common Stock Value StockIssuedConvertibleConversionOfCommonStockValue	0	USD
CY2017	us-gaap	Depreciation Depreciation	104704	USD
CY2016	us-gaap	Depreciation Depreciation	73059	USD
CY2017	us-gaap	Share Based Compensation ShareBasedCompensation	874386	USD
CY2016	us-gaap	Share Based Compensation ShareBasedCompensation	187306	USD
CY2017	us-gaap	Other Noncash Expense OtherNoncashExpense	451664	USD
CY2016	us-gaap	Other Noncash Expense OtherNoncashExpense	0	USD
CY2017	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	231717	USD
CY2016	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	0	USD
CY2017	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-262507	USD
CY2016	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	69779	USD
CY2017	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	239848	USD
CY2017	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	392315	USD
CY2016	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	91976	USD
CY2017	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4947982	USD
CY2016	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2888288	USD
CY2017	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	28737135	USD
CY2016	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	0	USD
CY2016	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	40903	USD
CY2017	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-28976983	USD
CY2016	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-40903	USD
CY2017	us-gaap	Proceeds From Issuance Of Common Limited Partners Units ProceedsFromIssuanceOfCommonLimitedPartnersUnits	0	USD
CY2016	us-gaap	Proceeds From Issuance Of Common Limited Partners Units ProceedsFromIssuanceOfCommonLimitedPartnersUnits	3718299	USD
CY2017	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	7493330	USD
CY2016	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	0	USD
CY2017	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	24109650	USD
CY2017	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	40961	USD
CY2016	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	USD
CY2017	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	855665	USD
CY2016	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0	USD
CY2017	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	30708406	USD
CY2016	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	3718299	USD
CY2017	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-3216559	USD
CY2016	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	789108	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5067240	USD
CY2017	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	844170	USD
CY2016	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	0	USD
CY2017	celc	Debt Discount Related To Investor And Agent Warrant DebtDiscountRelatedToInvestorAndAgentWarrant	1063715	USD
CY2016	celc	Debt Discount Related To Investor And Agent Warrant DebtDiscountRelatedToInvestorAndAgentWarrant	0	USD
CY2017	celc	Deferred Transaction Costs Included In Accounts Payable And Accrued Expenses DeferredTransactionCostsIncludedInAccountsPayableAndAccruedExpenses	2889	USD
CY2016	celc	Deferred Transaction Costs Included In Accounts Payable And Accrued Expenses DeferredTransactionCostsIncludedInAccountsPayableAndAccruedExpenses	0	USD
CY2017	celc	Ipo Costs Reduced In Cash Proceeds IpoCostsReducedInCashProceeds	275000	USD
CY2016	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	0	USD
CY2016	celc	Ipo Costs Reduced In Cash Proceeds IpoCostsReducedInCashProceeds	0	USD
CY2017Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	45000000	shares
CY2017Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2017Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2017Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2017Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	260119	USD
CY2016Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	155415	USD
CY2017	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	51455	USD
CY2016	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	49632	USD
CY2017Q4	us-gaap	Contractual Obligation Future Minimum Payments Due Remainder Of Fiscal Year ContractualObligationFutureMinimumPaymentsDueRemainderOfFiscalYear	200000	USD
CY2017Q4	us-gaap	Contractual Obligation Due In Third Year ContractualObligationDueInThirdYear	50000	USD
CY2017Q4	us-gaap	Contractual Obligation ContractualObligation	2040000	USD
CY2017	celc	Investment Warrant Exercise Price InvestmentWarrantExercisePrice	9.42
CY2016	celc	Investment Warrant Exercise Price InvestmentWarrantExercisePrice	7.56
CY2017Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	373323	shares
CY2016Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	55249	shares
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	302088	shares
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	501603	shares
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	114525	shares
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	233630	shares
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	190063	shares
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	34115	shares
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	2500	shares
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	201705	shares
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	71463	shares
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	5.91
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	3.07
CY2017	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	9.78
CY2016	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	7.6
CY2017	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	7.87
CY2016	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	3.6
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	7.58
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	5.8
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	2.91
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	6.35
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	5.22
CY2017Q2	celc	Proceeds From Issuance Of Convertible Debt Gross ProceedsFromIssuanceOfConvertibleDebtGross	8337500	USD
CY2017Q4	us-gaap	Long Term Investments LongTermInvestments	7205374	USD
CY2016Q4	us-gaap	Long Term Investments LongTermInvestments	0	USD
CY2017Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2016Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2017Q4	us-gaap	Common Unit Issued CommonUnitIssued	0	shares
CY2017Q4	us-gaap	Common Unit Outstanding CommonUnitOutstanding	0	shares
CY2016Q4	us-gaap	Common Unit Issued CommonUnitIssued	6440139	shares
CY2016Q4	us-gaap	Common Unit Outstanding CommonUnitOutstanding	6440139	shares
CY2016Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2016Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	0	shares
CY2017Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2016Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2016Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2017Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2016Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2016Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	0	shares
CY2017Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	10087516	shares
CY2017Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	10087516	shares
CY2016Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	0	shares
CY2016Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	0	shares
CY2015Q4	us-gaap	Stockholders Equity StockholdersEquity	5016421	USD
CY2017	celc	Stock Issued During Period Value Upon Exercise Of Warrants StockIssuedDuringPeriodValueUponExerciseOfWarrants	2052	USD
CY2017	us-gaap	Other Noncash Income OtherNoncashIncome	25097	USD
CY2016	us-gaap	Other Noncash Income OtherNoncashIncome	0	USD
CY2017	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	2052	USD
CY2016	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	USD
CY2017	us-gaap	Use Of Estimates UseOfEstimates	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><b><u><font style="FONT-SIZE: 10pt">Accounting Estimates</font></u></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Management uses estimates and assumptions in preparing these financial statements in accordance with U.S. GAAP. Those estimates and assumptions affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities, and the reported revenues and expenses. Actual results could differ from those estimates. Significant items subject to such estimates and assumptions include the valuation of stock-based compensation and warrants issued to investors, a placement agent and an underwriter, and prepaid or accrued clinical trial costs.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2017	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><b><u><font style="FONT-SIZE: 10pt">Risks and Uncertainties</font></u></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The Company is subject to risks common to companies in the development stage including, but not limited to, dependency on the clinical and commercial success of its diagnostic tests, ability to obtain regulatory approval of its diagnostic tests, the need for substantial additional financing to achieve its goals, uncertainty of broad adoption of its approved products, if any, by physicians and consumers, and significant competition.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2017Q4	us-gaap	Held To Maturity Securities Amortized Cost Before Other Than Temporary Impairment HeldToMaturitySecuritiesAmortizedCostBeforeOtherThanTemporaryImpairment	28762231	USD
CY2016Q4	us-gaap	Held To Maturity Securities Amortized Cost Before Other Than Temporary Impairment HeldToMaturitySecuritiesAmortizedCostBeforeOtherThanTemporaryImpairment	0	USD
CY2017	us-gaap	Stockholders Equity Note Stock Split StockholdersEquityNoteStockSplit	at a conversion ratio of 40 Units for one share of Common Stock.
CY2017	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	414	shares
CY2016	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	0	shares
CY2017Q4	us-gaap	Prepaid Insurance PrepaidInsurance	162914	USD
CY2016Q4	us-gaap	Prepaid Insurance PrepaidInsurance	0	USD
CY2017Q4	us-gaap	Prepaid Rent PrepaidRent	21673	USD
CY2016Q4	us-gaap	Prepaid Rent PrepaidRent	0	USD
CY2017Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	25121	USD
CY2016Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	0	USD
CY2017Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	540175	USD
CY2016Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	300327	USD
CY2017Q4	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	389802	USD
CY2016Q4	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	72917	USD
CY2017Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	61829	USD
CY2016Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	40341	USD
CY2017Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	54509	USD
CY2016Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	567	USD
CY2017Q2	us-gaap	Payments To Acquire In Process Research And Development PaymentsToAcquireInProcessResearchAndDevelopment	300000	USD
CY2017Q4	us-gaap	Payments To Acquire In Process Research And Development PaymentsToAcquireInProcessResearchAndDevelopment	50000	USD
CY2016	celc	Warrants Expiration Period WarrantsExpirationPeriod	P10Y
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0200	pure
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.750	pure
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.750	pure
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2017Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	2652723	USD
CY2017	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.35	pure
CY2017	celc	Income Tax Reconciliation Revaluation Of Deferred Tax Due Tax Reform IncomeTaxReconciliationRevaluationOfDeferredTaxDueTaxReform	366000	USD
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	5702716	USD
CY2017	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y6M22D
CY2017	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-682000	USD
CY2016	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	0	USD
CY2017	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-130000	USD
CY2016	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	0	USD
CY2017	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	897000	USD
CY2016	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	0	USD
CY2017Q4	celc	Employee Service Sharebased Compensation Nonvested Awards Compensation Cost Not Yet Recognizedwithin Two Years EmployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostNotYetRecognizedwithinTwoYears	829895	USD
CY2017	us-gaap	Income Tax Reconciliation Nondeductible Expense Other IncomeTaxReconciliationNondeductibleExpenseOther	3000	USD
CY2016	us-gaap	Income Tax Reconciliation Nondeductible Expense Other IncomeTaxReconciliationNondeductibleExpenseOther	0	USD
CY2017Q4	celc	Employee Service Sharebased Compensation Nonvested Awards Compensation Cost Not Yet Recognizedwithin Three Years EmployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostNotYetRecognizedwithinThreeYears	412803	USD
CY2016	celc	Income Tax Reconciliation Revaluation Of Deferred Tax Due Tax Reform IncomeTaxReconciliationRevaluationOfDeferredTaxDueTaxReform	0	USD
CY2017Q4	celc	Employee Service Sharebased Compensation Nonvested Awards Compensation Cost Not Yet Recognizedwithin Four Years EmployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostNotYetRecognizedwithinFourYears	299706	USD
CY2017Q4	celc	Employee Service Sharebased Compensation Nonvested Awards Compensation Cost Not Yet Recognizedwithin Five Years EmployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostNotYetRecognizedwithinFiveYears	116950	USD
CY2017	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	-454000	USD
CY2016	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	0	USD
CY2017Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	1659354	USD
CY2017Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	112000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	0	USD
CY2017Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	325000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	0	USD
CY2017Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	68000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	0	USD
CY2017Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	392000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	0	USD
CY2017Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	897000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	0	USD
CY2017Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2016Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2017Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	141456	USD
CY2017Q4	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	188850	USD
CY2017Q4	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	193338	USD
CY2017Q4	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	64940	USD
CY2017Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	588584	USD
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted	5250	shares
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	5250	shares
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	0	shares
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	0	shares
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	0	shares

Files In Submission

Name	View Source	Status
0001144204-18-014940-index-headers.html	Edgar Link	pending
0001144204-18-014940-index.html	Edgar Link	pending
0001144204-18-014940.txt	Edgar Link	pending
0001144204-18-014940-xbrl.zip	Edgar Link	pending
boulay_logo.jpg	Edgar Link	pending
celc-20171231.xml	Edgar Link	completed
celc-20171231.xsd	Edgar Link	pending
celc-20171231_cal.xml	Edgar Link	unprocessable
celc-20171231_def.xml	Edgar Link	unprocessable
celc-20171231_lab.xml	Edgar Link	unprocessable
celc-20171231_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
graph1.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
tv487729_10k.htm	Edgar Link	pending
tv487729_ex23-1.htm	Edgar Link	pending
tv487729_ex31-1.htm	Edgar Link	pending
tv487729_ex31-2.htm	Edgar Link	pending
tv487729_ex32-1.htm	Edgar Link	pending
tv487729_ex32-2.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CELC
Celcuity Inc Stock $celc

2018 Q1 Form 10-K Financial Statement

#000114420418014940 Filed on March 15, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CELC Celcuity Inc Stock $celc

2018 Q1 Form 10-K Financial Statement

#000114420418014940 Filed on March 15, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CELC
Celcuity Inc Stock $celc